This TCGA level 3 dataset, its clinical annotation and the published molecular subtype calls were obtained through the TCGA website [ 16].
Our findings did not support an association between the uptake of either radiopharmaceutical and molecular subtype.
Molecular characterization and novel therapeutic targets of each molecular subtype have been identified.
The biological conformity observed within each consensus molecular subtype (CMS) holds promise for the design of subtype-specific treatment regimens.
Molecular classification of a patient's disease should improve choices of therapy at diagnosis, given a particular molecular subtype, and lead to development of new therapies for subtypes with a poor prognosis.
Our findings did not support an association between the uptake of either radiopharmaceutical and tumor molecular subtype.
Molecular subtype of malignant lesions was characterized as luminal (ER+ and HER2−), HER2-enriched (HER2+/ER−/PR−), or triple negative (ER−/PR−/HER2−).
Mazurowski et al [38] found that the Luminal B molecular subtype is associated with enhancement dynamics on MRI.
With regard to molecular subtype, no correlation was observed between tumour immune subtype and molecular subtype.
Molecular subtype assignment according to the subtype clustering method [ 17].
